TY - JOUR
T1 - Antiandrogenic therapy can cause coronary arterial disease
AU - Chen, Kuan Chou
AU - Peng, Chiung Chi
AU - Hsieh, Hsiu Mei
AU - Peng, Chiung Huei
AU - Hsieh, Chiu Lan
AU - Huang, Chien Ning
AU - Chyau, Charng Cherng
AU - Wang, Hui Er
AU - Peng, Robert Y.
PY - 2005/10
Y1 - 2005/10
N2 - Aim: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer. Materials and methods: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN 0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. Results: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. Conclusions: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II profiles, other than the well-known hyperglyceridemic effect caused by estrogen.
AB - Aim: To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer. Materials and methods: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II profiles in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN 0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. Results: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. Conclusions: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II profiles, other than the well-known hyperglyceridemic effect caused by estrogen.
KW - Antiandrogen
KW - CAD (coronary arterial disease)
KW - CPA (cyproterone acetate)
KW - Hormonal therapy
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=28444464037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28444464037&partnerID=8YFLogxK
U2 - 10.1111/j.1442-2042.2005.01145.x
DO - 10.1111/j.1442-2042.2005.01145.x
M3 - Article
C2 - 16323982
AN - SCOPUS:28444464037
SN - 0919-8172
VL - 12
SP - 886
EP - 891
JO - International Journal of Urology
JF - International Journal of Urology
IS - 10
ER -
